Pharnext AAQS 2024

מה עושה Pharnext?

Pharnext SA is a French biopharmaceutical company specializing in the development of innovative therapies for neurological diseases. The company was founded in 2007 by Professor Daniel Cohen and is headquartered in Paris. Pharnext's focus is on identifying synergistic effects of existing drugs to develop novel and effective therapies. The business model of Pharnext is based on the concept of "pleotherapy," which involves using multiple drugs simultaneously. These drug combinations are optimized to act synergistically and achieve better treatment outcomes than individual drugs alone. This allows Pharnext to achieve higher efficacy and lower toxicity. Pharnext operates in two main areas: developing therapies for neurological diseases such as Alzheimer's, Parkinson's, MND (Motoneuron Disease), Charcot-Marie-Tooth (CMT), and other rare diseases, and providing analysis and diagnostic tools for rare diseases. A significant product of Pharnext is PXT3003, a proprietary combination of three drugs for the treatment of Charcot-Marie-Tooth (CMT). PXT3003 is in Phase III clinical development and has the potential to be a groundbreaking therapy for one of the most common hereditary neuropathies worldwide. The company is also developing other products, such as PXT864 for Alzheimer's, PXT002331 for Parkinson's, and PXT002331 for MND, all of which are in clinical development. Pharnext also collaborates with other biotech and pharmaceutical companies to leverage synergies and advance the development of its therapies. For example, the company collaborates with Ipsen for the development of PXT3003 and with Galapagos for the development of drug candidates against inflammatory diseases. Overall, Pharnext aims to take a leading role in the development of therapies for neurological diseases. The company focuses on innovative approaches to maximize the potential of drug combinations and develop novel and effective therapies. Pharnext ist eines der beliebtesten Unternehmen auf Eulerpool.com.